What Are OXPHOS Antibodies?

OXPHOS antibodies are specialized antibodies used to detect proteins involved in mitochondrial oxidative phosphorylation (OXPHOS), the process by which cells generate adenosine triphosphate (ATP) via the electron transport chain. These antibodies help researchers and clinicians identify, quantify and analyze mitochondrial proteins involved in cellular energy production.¹

Oxidative phosphorylation occurs across the inner mitochondrial membrane and involves five major protein complexes (Complexes I–V). OXPHOS antibodies are commonly designed to target one or more subunits of these complexes, enabling scientists to assess mitochondrial function, protein expression and respiratory chain integrity.¹

These antibodies are widely used in applications such as Western blotting, immunofluorescence, immunohistochemistry, ELISA and flow cytometry. In research settings, they support studies related to metabolism and aging, as well as mitochondrial dysfunction underlying neurodegenerative disorders and cancer. In clinical and translational research, OXPHOS antibodies may also help investigate biomarkers for inherited mitochondrial diseases and metabolic disorders.^2,3

The Importance of OXPHOS Antibodies in Mitochondrial Research

OXPHOS antibodies play a critical role in mitochondrial research by helping scientists investigate how cells produce energy and how mitochondrial dysfunction contributes to disease. Because oxidative phosphorylation is the primary pathway responsible for ATP generation, abnormalities in OXPHOS proteins can significantly affect cellular metabolism, signaling and survival.⁴

Researchers commonly use OXPHOS antibodies to study the expression, localization and integrity of proteins within the mitochondrial electron transport chain (ETC). These antibodies support investigations into conditions associated with impaired mitochondrial function, including neurodegenerative diseases, metabolic disorders, cardiovascular disease, cancer and aging-related cellular decline.^5-7 They are also valuable for evaluating ATP synthesis efficiency and identifying defects in specific respiratory chain complexes.⁸

The five major OXPHOS complexes commonly studied include:

• Key Complexes:

  • Complex I (NADH dehydrogenase): Transfers electrons from NADH to ubiquinone and contributes to proton pumping across the mitochondrial membrane⁹
  • Complex II (Succinate dehydrogenase): Links the tricarboxylic acid (TCA) cycle to the electron transport chain by transferring electrons from succinate to fumarate¹⁰
  • Complex III (Cytochrome bc1): Facilitates electron transfer from ubiquinol to cytochrome c while supporting proton translocation¹¹
  • Complex IV (Cytochrome c oxidase): Transfers electrons from cytochrome c to oxygen, the terminal electron acceptor, forming water¹²
  • Complex V (ATP synthase): Uses the proton gradient generated by the ETC to synthesize ATP¹³

Together, these complexes maintain cellular energy homeostasis, making OXPHOS antibodies essential tools for mitochondrial biology, bioenergetics and disease research.

Mapping the Electron Transport Chain (ETC): Complex-Specific Targets

OXPHOS antibodies are frequently generated against specific subunits within each electron transport chain (ETC) complex, enabling researchers to assess mitochondrial composition, respiratory chain integrity and complex assembly.

From Complex I to Complex V, key subunit antibodies are summarized below:

• Complex I (NADH dehydrogenase): The Anti-NDUFB8 antibody targets a subunit of Complex I and is commonly used as a marker for Complex I assembly and expression. Because Complex I is one of the largest and most intricate ETC complexes, NDUFB8 detection can help researchers identify defects associated with mitochondrial disorders and impaired oxidative phosphorylation.⁵
• Complex II (Succinate dehydrogenase): The Anti-SDHB antibody targets the succinate dehydrogenase subunit B protein, a key component of both the TCA cycle and the ETC. SDHB expression analysis is frequently used in cancer research, mitochondrial disease studies and investigations involving metabolic dysfunction.¹⁴
• Complex III (Cytochrome bc1): The Anti-UQCRC2 antibody recognizes a core protein within Complex III and is widely used to assess mitochondrial respiratory chain stability and protein abundance. UQCRC2 is often included in OXPHOS antibody panels designed to evaluate overall mitochondrial integrity.¹⁵
• Complex IV (Cytochrome c oxidase): The Anti-MTCO1 antibody targets a mitochondrially encoded subunit of cytochrome c oxidase. MTCO1 detection is especially valuable for studying mitochondrial DNA-encoded proteins, respiratory deficiencies and mitochondrial translation defects.¹⁶
• Complex V (ATP synthase): The Anti-ATP5A antibody detects a major catalytic subunit of ATP synthase and is commonly used to evaluate ATP production machinery within mitochondria. ATP5A measurement helps researchers investigate cellular energy metabolism, mitochondrial biogenesis and OXPHOS efficiency. ¹⁷

Different Forms of OXPHOS Antibodies

OXPHOS antibodies are available in several formats, each designed to support different experimental goals and detection strategies in mitochondrial research. Selecting the appropriate antibody type depends on factors such as specificity, sensitivity, multiplexing needs and assay application.

Monoclonal vs Polyclonal OXPHOS Antibodies

Monoclonal OXPHOS antibodies are produced from a single immune cell clone and recognize one specific epitope on a target protein. Because of their high specificity and batch-to-batch consistency, monoclonal antibodies are widely used in quantitative studies, diagnostic workflows and experiments requiring reproducible results.¹⁸

In contrast, polyclonal OXPHOS antibodies are mixtures that recognize multiple epitopes on the same protein. This broader binding profile can improve signal strength and detection sensitivity, especially when target proteins are expressed at low levels or partially denatured. Polyclonal antibodies are often useful for exploratory research and certain immunoprecipitation or immunofluorescence applications.¹⁹

Total OXPHOS Antibody Cocktail

A total OXPHOS antibody cocktail combines multiple antibodies targeting representative subunits from Complexes I–V into a single reagent. This approach allows researchers to evaluate multiple mitochondrial respiratory chain complexes simultaneously in a single assay or blot.²⁰

These cocktails are commonly used for:^21,22

• Comparing relative expression levels across ETC complexes
• Monitoring mitochondrial content and integrity
• Detecting broad respiratory chain deficiencies
• Streamlining multiplex mitochondrial analyses

Because multiple complexes can be assessed in a single reaction, OXPHOS antibody cocktails help reduce sample usage, assay time and experimental variability.²²

OXPHOS Antibody Panel

An OXPHOS antibody panel provides a more comprehensive set of antibodies designed for detailed analysis of mitochondrial respiratory chain function and deficiencies. These panels comprise antibodies against multiple subunits within each ETC complex, along with mitochondrial loading controls or markers associated with mitochondrial biogenesis.¹⁹

Researchers use OXPHOS antibody panels to:^19,23

• Investigate inherited mitochondrial disorders
• Characterize metabolic and neurodegenerative diseases
• Study cancer-associated mitochondrial remodeling
• Evaluate drug-induced mitochondrial toxicity
• Analyze mitochondrial dysfunction in translational research·

By providing broad coverage of oxidative phosphorylation proteins, OXPHOS antibody panels enable a more detailed and systematic assessment of mitochondrial health and bioenergetic status.

Choosing the Right OXPHOS Antibody for Your Experiment

Selecting the appropriate OXPHOS antibody is essential for generating reliable and reproducible mitochondrial research data. The ideal antibody depends on several factors, including the target species, sample type, detection method and the level of specificity required for the experiment.

Specificity: Matching the Antibody to Your Research Needs

One of the most important considerations when choosing an OXPHOS antibody is target specificity. Researchers should confirm that the antibody has been validated for the species and application being used, such as human, mouse, rat or other model systems.

Sample type also plays a critical role. Certain OXPHOS antibodies perform best with isolated mitochondrial fractions, whereas others are validated for whole-cell lysates, tissue sections or fixed cells. Researchers studying mitochondrial dysfunction may additionally require antibodies capable of detecting native, denatured or post-translationally modified proteins, depending on the assay format.²⁴

Additional factors to evaluate include:¹⁹

• Sensitivity and signal intensity
• Cross-reactivity with related proteins
• Compatibility with multiplex detection workflows
• Published validation data and peer-reviewed references

Antibody Formats: Monoclonal, Polyclonal or Cocktail?

Different antibody formats offer distinct advantages depending on the experimental objective and detection method.

Monoclonal antibodies are highly specific and recognize a single epitope on the target protein. They are often preferred for quantitative assays and experiments requiring high reproducibility and low background staining.²⁵

Polyclonal antibodies recognize multiple epitopes on the same protein, thereby improving detection sensitivity and signal amplification. These antibodies may be advantageous when studying low-abundance mitochondrial proteins or partially denatured samples.²⁶

OXPHOS antibody cocktails combine antibodies against multiple ETC complexes into a single reagent, enabling simultaneous analysis of multiple mitochondrial targets in a single experiment. This format is especially useful for comparative respiratory chain profiling. ¹⁹

The ultimate choice between monoclonal, polyclonal and cocktail-based approaches should align with the study design, detection platform and desired balance between specificity and sensitivity.

Techniques for Detecting OXPHOS Complexes

Western Blot

Western blotting is one of the most widely used methods for analyzing OXPHOS protein expression. Researchers commonly use OXPHOS antibody cocktails to simultaneously detect representative subunits from Complexes I–V in a single assay, allowing efficient comparison of mitochondrial respiratory chain components.³

Immunohistochemistry (IHC)

Immunohistochemistry uses OXPHOS antibodies to visualize mitochondrial proteins within tissue sections. This technique helps researchers examine mitochondrial distribution, tissue-specific expression patterns and respiratory chain deficiencies in clinical and research samples.⁵

Immunofluorescence (IF)

Immunofluorescence allows the detection of OXPHOS complexes at the single-cell level using fluorescently labeled antibodies. It is particularly useful for studying mitochondrial morphology, localization and cellular heterogeneity associated with mitochondrial dysfunction.¹⁹

Flow Cytometry & ELISA

Flow cytometry and ELISA are commonly used for quantitative analysis of OXPHOS protein expression across different sample types. These methods support high-throughput measurement of mitochondrial markers and are valuable for comparative studies, biomarker analysis, and drug response assessments.²⁷

OXPHOS Antibody Cocktail vs Individual Antibodies

Researchers can choose between an OXPHOS antibody cocktail and individual antibodies, depending on the goals of the experiment, the level of detail required and the detection workflow.

An OXPHOS antibody cocktail enables simultaneous detection of Complexes I–V in a single experiment, making it ideal for rapid mitochondrial profiling and comparative analysis. From this perspective, they help simplify workflows, reduce processing time and improve consistency across samples. In contrast, individual OXPHOS antibodies provide greater flexibility and are often preferred when researchers need detailed analysis of a specific ETC complex, protein isoform or signaling pathway. Individual antibodies may also offer greater control over optimization for specialized applications.²⁸

Nevertheless, OXPHOS antibody cocktails can significantly reduce experimental costs by minimizing the number of separate antibody incubations and reagents required. They also help conserve valuable biological material by requiring smaller sample volumes compared with running multiple individual blots. As a result, OXPHOS antibody cocktails are especially useful when working with limited mitochondrial samples or clinical specimens. ²⁸

Clinical and Research Applications: From Cancer to Rare Diseases

Metabolic Reprogramming in Cancer Research

OXPHOS antibodies are widely used in cancer research to investigate metabolic reprogramming and mitochondrial dependence in tumor cells. In cancers such as pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer, researchers use OXPHOS antibodies to investigate elevated oxidative phosphorylation activity, mitochondrial adaptation and potential therapeutic targets in high-OXPHOS tumor populations.²

Diagnosing Mitochondrial Myopathy and Disorders:

OXPHOS antibodies also support the investigation and diagnosis of mitochondrial diseases by detecting deficiencies in respiratory chain complexes. They can help identify heteroplasmic mitochondrial DNA (mtDNA) defects and characterize disorders such as MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes) and MERRF (Myoclonic Epilepsy with Ragged Red Fibers) by analyzing ETC protein expression patterns.²⁹ Alongside this, in muscle tissue studies, OXPHOS antibodies are used to detect focal respiratory chain deficiencies associated with mitochondrial myopathies, aging skeletal muscle and neurodegenerative conditions such as Parkinson’s disease.⁷

Biological Context and Functional Pathways of OXPHOS Antibodies

Mitochondrial Dysfunction

OXPHOS antibodies are important tools for studying mitochondrial dysfunction and its effects on cellular health. Researchers use these antibodies to investigate oxidative stress, mitochondrial quality control defects and defective mitophagy. Changes in OXPHOS protein expression can also provide insight into cellular stress responses and mitochondrial damage linked to aging and disease.³⁰

Mitochondrial Biogenesis

OXPHOS antibodies are commonly used to evaluate mitochondrial biogenesis by monitoring the expression of respiratory chain proteins during mitochondrial growth and adaptation. Measuring OXPHOS complex levels helps researchers assess changes in mitochondrial content, energy metabolism and overall function during physiological stress, exercise, drug treatment or disease progression.³¹

Protocols for Success: How to Use OXPHOS Antibodies in the Lab

Sample Preparation and Western Blot (WB) Optimization

Proper sample preparation is essential for accurate detection of OXPHOS proteins. During Western blot workflows, many mitochondrial membrane proteins become susceptible to harsh denaturation conditions. ³²

A typical workflow has a critical “no-boil” principle. OXPHOS samples are often prepared without boiling because excessive heat can cause aggregation of mitochondrial membrane proteins, reducing detection quality and band resolution.³²

Determining the correct antibody dilution is important for balancing signal strength and background reduction. Optimal dilution ratios for OXPHOS antibody cocktails may vary depending on sample type, protein abundance and detection system. ³²

Imaging Techniques: IHC, IF and Flow Cytometry:

OXPHOS antibodies are widely used in imaging-based mitochondrial analysis. In immunohistochemistry (IHC), OXPHOS antibodies help visualize respiratory chain protein expression in tissue samples such as skeletal muscle biopsies. Furthermore, quadruple immunofluorescence staining with OXPHOS antibodies allows researchers to detect mitochondrial deficiencies at the single-cell level and identify heterogeneous respiratory chain defects within tissues.¹⁹

Choosing the Right Tool: Total OXPHOS Antibody Cocktail vs. Individual Panels

Advantages of the Total OXPHOS Antibody Cocktail

The right OXPHOS antibody tool depends on the specific application and research questions. That said, OXPHOS cocktails offer several advantages over individual panels. A total OXPHOS antibody cocktail reduces sample and reagent consumption by enabling simultaneous analysis of multiple ETC complexes. This capacity greatly diminishes the required sample volume compared to running separate Western blots for individual antibodies. In addition, OXPHOS antibody cocktails enable the detection of representative subunits from all five mitochondrial complexes in a single Western blot lane, improving workflow efficiency and comparative analysis.³³

Nevertheless, the choice between an antibody cocktail vs. individual panels is one of many considerations.

Species and Format Considerations

Certain antibodies are optimized specifically for human samples, while others are designed for mouse or rat tissues. Therefore, researchers should select OXPHOS antibodies validated for the species employed in their experimental model. ¹⁹

When selecting the format, the downstream application is the critical factor in deciding between monoclonal and polyclonal OXPHOS antibodies. Monoclonal OXPHOS antibodies are often preferred for diagnostic and quantitative applications because they provide high specificity, consistency and reproducibility across experiments.³⁴

References

1. Zotta A, O’Neill LA, Yin M. Unlocking potential: the role of the electron transport chain in immunometabolism. Trends Immunol 2024;45(4):259-273.
2. Qiu X, Li Y, Zhang Z. Crosstalk between oxidative phosphorylation and immune escape in cancer: a new concept of therapeutic targets selection. Cell Oncol 2023;46(4):847-865.
3. Teixeira RB, Pfeiffer M, Zhang P, Shafique E, Rayta B, Karbasiafshar C, et al. Reduction in mitochondrial ROS improves oxidative phosphorylation and provides resilience to coronary endothelium in non-reperfused myocardial infarction. Basic Res Cardiol 2023;118(1):3.
4. Koc EC, Koc FC, Kartal F, Tirona M, Koc H. Role of mitochondrial translation in remodeling of energy metabolism in ER/PR (+) breast cancer. Front Oncol 2022;12:897207.
5. Tian J, Luo J, Zeng X, Ke C, Wang Y, Liu Z, et al. Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma. J Immunother Cancer 2024;12(2):e008226.
6. Gordon-Lipkin EM, Banerjee P, Franco JLM, Tarasenko T, Kruk S, Thompson E, et al. Primary oxidative phosphorylation defects lead to perturbations in the human B cell repertoire. Front Immunol 2023;14:1142634.
7. Chen C, Mossman E, Malko P, McDonald D, Blain AP, Bone L, et al. Astrocytic changes in mitochondrial oxidative phosphorylation protein levels in Parkinson's disease. Mov Disord 2022;37(2):302-314.
8. Wang T, Sun F, Li C, Nan P, Song Y, Wan X, et al. MTA1, a novel ATP synthase complex modulator, enhances colon cancer liver metastasis by driving mitochondrial metabolism reprogramming. Adv Sci 2023;10(25):2300756.
9. Jiménez-Gómez B, Ortega-Sáenz P, Gao L, González-Rodríguez P, García-Flores P, Chandel N, et al. Transgenic NADH dehydrogenase restores oxygen regulation of breathing in mitochondrial complex I-deficient mice. Nat Commun 2023;14(1):1172.
10. Bénit P, Goncalves J, El Khoury R, Rak M, Favier J, Gimenez-Roqueplo A-P, et al. Succinate dehydrogenase, succinate, and superoxides: a genetic, epigenetic, metabolic, environmental explosive crossroad. Biomedicines 2022;10(8):1788.
11. Esser L, Xia D. Mitochondrial cytochrome bc 1 complex as validated drug target: A structural perspective. Trop Med Infect Dis 2024;9(2):39.
12. Brischigliaro M, Zeviani M. Cytochrome c oxidase deficiency. Biochimica et Biophysica Acta (BBA)-Bioenergetics 2021;1862(1):148335.
13. Lai Y, Zhang Y, Zhou S, Xu J, Du Z, Feng Z, et al. Structure of the human ATP synthase. Mol Cell 2023;83(12):2137-2147. e4.
14. Ornstead MJ, Sirohi D, Albertson DJ, Greenberg SE, Mahlow J. Expression Patterns of Succinate Dehydrogenase B: An Immunohistochemical Study of 57 Tumors With Known SDHx Germline Pathogenic Alterations. Int J Surg Pathol 2026:10668969261439732.
15. Matassa DS, Criscuolo D, Avolio R, Agliarulo I, Sarnataro D, Pacelli C, et al. Regulation of mitochondrial complex III activity and assembly by TRAP1 in cancer cells. Cancer Cell Int 2022;22(1):402.
16. Deng M, Zhou Z, Chen J, Li X, Liu Z, Ye J, et al. Enhanced oxidative phosphorylation driven by TACO1 mitochondrial translocation promotes stemness and cisplatin resistance in bladder cancer. Adv Sci 2025;12(5):2408599.
17. Chang Y-W, Tony Yang T, Chen M-C, Liaw Y-g, Yin C-F, Lin-Yan X-Q, et al. Spatial and temporal dynamics of ATP synthase from mitochondria toward the cell surface. Commun Biol 2023;6(1):427.
18. Santos D, Santos C, Artuch R, Marco MP, Pascual N. Novel Monoclonal Antibody for Coenzyme Q10: A diagnostic tool for mitochondrial OXPHOS diseases. 2025.
19. Sachdeva A, Hart CA, Carey CD, Vincent AE, Greaves LC, Heer R, et al. Automated quantitative high-throughput multiplex immunofluorescence pipeline to evaluate OXPHOS defects in formalin-fixed human prostate tissue. Sci Rep 2022;12(1):6660.
20. Ramchandani D, Berisa M, Tavarez DA, Li Z, Miele M, Bai Y, et al. Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis. Nat Commun 2021;12(1):7311.
21. Yanar S, Kasap M, Kanli A, Akpinar G, Sarihan M. Proteomics analysis of meclofenamic acid‐treated small cell lung carcinoma cells revealed changes in cellular energy metabolism for cancer cell survival. J Biochem Mol Toxicol 2023;37(4):e23289.
22. Yoon H, Park SG, Kim H-J, Shin H-R, Kim K-T, Cho Y-D, et al. Nicotinamide enhances osteoblast differentiation through activation of the mitochondrial antioxidant defense system. Exp Mol Med 2023;55(7):1531-1543.
23. Evans KW, Yuca E, Scott SS, Zhao M, Paez Arango N, Cruz Pico CX, et al. Oxidative phosphorylation is a metabolic vulnerability in chemotherapy-resistant triple-negative breast cancer. Cancer Res 2021;81(21):5572-5581.
24. Sabbir MG, Taylor CG, Zahradka P. CAMKK2 regulates mitochondrial function by controlling succinate dehydrogenase expression, post-translational modification, megacomplex assembly, and activity in a cell-type-specific manner. Cell Commun Signal 2021;19(1):98.
25. Alhazmi HA, Albratty M. Analytical techniques for the characterization and quantification of monoclonal antibodies. Pharmaceuticals 2023;16(2):291.
26. Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med 2021;27(4):717-726.
27. Liu M, Fu X, Yi Q, Xu E, Dong L. Impaired mitochondrial oxidative phosphorylation induces CD8+ T cell exhaustion. Biochem Biophys Res Comm 2024;734:150738.
28. Zhang B, Feng H, Lin H, Li R. Somatostatin-SSTR3-GSK3 modulates human T-cell responses by inhibiting OXPHOS. Front Immunol 2024;15:1322670.
29. Machida A, Shirai K, Oyama J, Usui E, Kakuta T. MERRF/MELAS overlap syndrome mimicking paradoxical cerebral embolism due to patent foramen ovale. Neurol Sci 2026;47(4):395.
30. Dontaine J, Bouali A, Daussin F, Bultot L, Vertommen D, Martin M, et al. The intra-mitochondrial O-GlcNAcylation system rapidly modulates OXPHOS function and ROS release in the heart. Commun Biol 2022;5(1):349.
31. Wang Y, Tang B, Long L, Luo P, Xiang W, Li X, et al. Improvement of obesity-associated disorders by a small-molecule drug targeting mitochondria of adipose tissue macrophages. Nat Commun 2021;12(1):102.
32. Guo L, Zhang B, Zhang W, Xie Y, Chen X, Sun X, et al. Inhibition of carbohydrate metabolism potentiated by the therapeutic effects of oxidative phosphorylation inhibitors in colon cancer cells. Cancers (Basel) 2024;16(7):1399.
33. Chen C, McDonald D, Blain A, Sachdeva A, Bone L, Smith AL, et al. Imaging mass cytometry reveals generalised deficiency in OXPHOS complexes in Parkinson’s disease. npj Parkinson's Disease 2021;7(1):39.
34. Merlin J, Ivanov S, Dumont A, Sergushichev A, Gall J, Stunault M, et al. Non-canonical glutamine transamination sustains efferocytosis by coupling redox buffering to oxidative phosphorylation. Nat Metab 2021;3(10):1313-1326.